Feb 2019 $199 M No. 8 $50 to $250 million 45
Intarcia Therapeutics, Inc.: Raise no. 8, Feb 2019 × Investors in this round 45 investors had bought by the notice of Jan 14, 2020: 45 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $199 M of $280 M offered; $82 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $3,000,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Anders Vinther · Executive Officer David Spellman · Executive Officer Fred Fiedorek · Executive Officer Kurt Graves · Executive Officer, Director Paul Feldman · Executive Officer Raymond Keane · Executive Officer Thane Wettig · Executive Officer Bob Kerrey · Director Bryan Roberts · Director Gino Santini · Director Jay Skyler · Director Jim Rosenthal · Director Nancy Thornberry · Director Patrick Conway · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Morgan Stanley & Co. LLC (CRD 8209) · New York, New York Sold in CA, MA, NC, NJ, PA, SD Signed by Kurt Graves, Chief Executive Officer. Newest notice filed Jan 14, 2020. Read the notice at the SEC .
debt, options SEC Sep 2016 $525 M No. 7 $250 million to $1 billion 90
Intarcia Therapeutics, Inc.: Raise no. 7, Sep 2016 × Investors in this round 90 investors had bought by the notice of Aug 4, 2017: 90 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $525 M of $850 M offered; $325 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions $15,908,222
Finders' fees $218,015
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Anthony Hurley · Executive Officer James Ahlers · Executive Officer Jay Smith · Executive Officer John Yee · Executive Officer Kurt Graves · Executive Officer, Director Michelle Baron · Executive Officer Owen Hughes, Jr. · Executive Officer Paul Feldman · Executive Officer Raymond Keane · Executive Officer Sunita Zalani · Executive Officer Thomas Alessi · Executive Officer Bryan Roberts · Director Emad Rizk · Director Gino Santini · Director Glen Sato · Director Irwin Scher · Director Nancy Thornberry · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Raptor International, LLC · Abu Dhabi, United Arab Emirates Sold in no state named, and outside the US UBS Securities LLC (CRD 7654) · City State/Province/Country Zi, New York Sold in AL, AR, AZ, CA, CO, CT, FL, GA, IL, IN, LA, MA, MI, MN, MT, NC, NE, NH, NJ, NV, NY, OK, PA, SC, TN, TX, VA, WA, WY, and outside the US Brooklands Capital Strategies BD, LP · Fort Worth, Texas Sold in all US states, and outside the US OUISA CAPITAL, LLC · New York, New York Sold in all US states Morgan Stanley & Co. LLC (CRD 8209) · New York, New York Sold in AL, AR, AZ, CA, CO, CT, DC, FL, GA, IA, IL, KS, LA, MA, MD, MI, MO, MS, NC, NJ, NV, NY, OH, OK, PA, RI, SC, TN, TX, VA, WA, and outside the US Signed by Raymond T. Keane, Vice President, General Counsel and Chief Legal Officer. Newest notice filed Aug 4, 2017 (3 amendments). Read the notice at the SEC .
equity SEC Mar 2014 $200 M No. 6 $50 to $250 million 38
Intarcia Therapeutics, Inc.: Raise no. 6, Mar 2014 × Investors in this round 38 investors had bought by the notice of Apr 7, 2014: 38 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $200 M of $200 M offered
Smallest investment taken $14,446
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Franklin · Executive Officer James Ahlers · Executive Officer Jay T. Smith · Executive Officer Kurt Graves · Executive Officer, Director Michelle Baron · Executive Officer Owen Hughes, Jr. · Executive Officer Raymond T. Keane · Executive Officer Thomas Alessi · Executive Officer Bryan T. Roberts · Director Gino Santini · Director Glen Sato · Director Irwin Scher · Director Nancy Thornberry · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Raymond T. Keane, Vice President, General Counsel and Chief Legal Officer. Newest notice filed Apr 7, 2014. Read the notice at the SEC .
equity SEC Nov 2012 $8 M No. 5 $2 to $10 million 15
Intarcia Therapeutics, Inc.: Raise no. 5, Nov 2012 × Investors in this round 15 investors had bought by the notice of Nov 29, 2012: 15 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $8 M of $8 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Barbara McClung · Executive Officer David Franklin · Executive Officer James Ahlers · Executive Officer Kurt Graves · Executive Officer, Director Michelle Baron · Executive Officer Thomas Alessi · Executive Officer Ed Mathers · Director Glen Sato · Director Irwin Scher · Director James Niedel · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Repayment of debt.”Signed by Barbara McClung, Secretary. Newest notice filed Nov 29, 2012 (1 amendment). Read the notice at the SEC .
equity SEC Aug 2012 $7 M No. 4 $2 to $10 million 1
Intarcia Therapeutics, Inc.: Raise no. 4, Aug 2012 × Investors in this round 1 investor had bought by the notice of Aug 22, 2012: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $7 M of $7 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Barbara J. McClung · Executive Officer David J. Franklin · Executive Officer James Ahlers · Executive Officer Kurt Graves · Executive Officer, Director Michelle J. Baron · Executive Officer Thomas J. Alessi · Executive Officer Bryan J. Roberts · Director Ed J. Mathers · Director Glen J. Sato · Director Irwin J. Scher · Director James J. Niedel · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Working capital and general corporate purposes.”Signed by Barbara McClung, Secretary. Newest notice filed Aug 22, 2012. Read the notice at the SEC .
debt, options SEC Aug 2010 $46 M No. 3 $10 to $50 million 35
Intarcia Therapeutics, Inc.: Raise no. 3, Aug 2010 × Investors in this round 35 investors had bought by the notice of Aug 30, 2012: 35 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $46 M of $48 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Barbara J. McClung · Executive Officer David J. Franklin · Executive Officer James Ahlers · Executive Officer Kurt Graves · Executive Officer, Director Michelle J. Baron · Executive Officer Thomas J. Alessi · Executive Officer Bryan J. Roberts · Director Ed J. Mathers · Director Glen J. Sato · Director Irwin J. Scher · Director James J. Niedel · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Working capital and general corporate purposes.”Signed by Barbara McClung, Secretary. Newest notice filed Aug 30, 2012 (3 amendments). Read the notice at the SEC .
debt, options SEC Mar 2010 $14 M No. 2 $10 to $50 million 30
Intarcia Therapeutics, Inc.: Raise no. 2, Mar 2010 × Investors in this round 30 investors had bought by the notice of May 14, 2010: 30 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $14 M of $16 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Barbara G. McClung · Executive Officer David J. Franklin · Executive Officer James M. Ahlers · Executive Officer K. Alice Leung · Executive Officer, Director Kenneth L. Luskey · Executive Officer Thomas R. Alessi · Executive Officer Bryan R. Roberts · Director Ed R. Mathers · Director Glen R. Sato · Director Irwin R. Scher · Director James R. Niedel · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Includes loan amount and warrant purchase price. It does not include the exercise price of the shares.”On the use of proceeds: “Proceeds will be used for working capital.”Signed by Barbara G. McClung, V.P., General Counsel, Secretary. Newest notice filed May 14, 2010. Read the notice at the SEC .
equity, debt, options SEC Nov 2009 $9 M No. 1 $2 to $10 million 33
Intarcia Therapeutics, Inc.: Raise no. 1, Nov 2009 × Investors in this round 33 investors had bought by the notice of Jan 15, 2010: 33 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $9 M of $9 M offered
Smallest investment taken no minimum stated
What was sold equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Barbara G. McClung · Executive Officer David J. Franklin · Executive Officer James M. Ahlers · Executive Officer K. Alice Leung · Executive Officer, Director Kenneth L. Luskey · Executive Officer Thomas R. Alessi · Executive Officer Bryan R. Roberts · Director Ed R. Mathers · Director Glen R. Sato · Director Irwin R. Scher · Director James R. Niedel · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Includes loan amount, price of Series BB shares sold and warrant purchase price. It does not include the exercise price of the shares.”On the use of proceeds: “Proceeds will be used for working capital.”Signed by Barbara G. McClung, V.P., General Counsel, Secretary. Newest notice filed Jan 15, 2010 (1 amendment). Read the notice at the SEC .
equity, debt, options SEC